Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast CarcinomaStatus: open
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Treatment for Breast Cancer
The purpose of this study is to assess the effect of tucatinib vs. placebo in combination with capecitabine and trastuzumab on progression-free survival (PFS) per RECIST 1.1 based on independent central review.
SponsorsThis trial is sponsored by Cascadian Therapeutics.
Interested in Clinical Trial?
Providers Associated With This Trial
- Daniel G. Cameron, M.D.Medical OncologistSenior Staff Medical Oncologist, Medical Oncology Service; Associate Professor of Interdisciplinary Clinical Oncology